Connect with us

Business

Kalytera Therapeutics Inc (OTCMKTS:KALTF) Provides Details About Its Latest Notice Of Allowance

Published

on

Kalytera Therapeutics Inc (OTCMKTS:KALTF) has today revealed details regarding the EU Patent Application Number 14791611.8. According to the company, the European Patent Office directed a Notice of Allowance to this application. This application focuses on the importance of cannabidiol (“CBD”) in treating graft versus host disease (“GVHD”).

Details about the patent

Kalytera Therapeutics takes immense pride in having exclusive worldwide rights to the patent. It got to this point after coming together with MOR Research Applications, Ltd. of Israel, and signing an Exclusive License Agreement. Top officials admit that it wasn’t easy securing this European patent and see it as a game-changer.

The company wants to use its resources to develop as well as commercialize CBD. That is a way to intervene and save patients from GVHD, which is a life-threatening disease. Chief Executive Officer Robert Farrell is pleased that the latest achievement happens during his term in office.

He opines, “Patients receiving bone marrow transplants are at high risk of developing acute GVHD, a complication that occurs when the transplanted donor cells attack the patient’s organs, including the skin, GI tract, liver, lungs, and eyes.”

A plan into the future

He reveals that so far, FDA hasn’t approved any therapies for fighting or preventing acute GVHD. The company’s priority at the moment is to complete the required procedure so that it can be issued the patent. An official working with it say they are making preparations early in advance. They are also filing translations of this patent into German and French. Hopefully, by January next year, Kalytera will have completed these procedures.

This will be the third patent for the company in line with the usage of CBD to prevent or treat GVHD.

The other achievement by the company is the receiving of some four orphan drug designations to treat and prevent GVHD. This was to be used in handling patients in Europe and the U.S. Back in 2017, the company succeeded in the acquisition of a program and promised to combat GVHD. This became possible through the signing of an agreement with Talent Biotechs, Ltd. of Israel.

As part of the deal, the company committed to giving some funds to former Talent shareholders. More discussions about this deal are still underway.

Business

OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) Subsidiary’s Cannabis Product Performs Remarkably

Published

on

By

OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) is an industry leader in the development of cannabinoid-based therapies. Some of this company’s leading products help treat a wide range of medical disorders and conditions.

Nature of the research

This company’s subsidiary, One World Cannabis, has been researching its Medical Grade Cannabis. It has unveiled the results of the research terming them Top Line. This was a single-dose, randomized, crossover study that sought to compare several aspects of the medical solutions. Among them included the safety, tolerability, and pharmacokinetics (PK) of the buccal Sativex® versus the Orally Disintegrating Tablets (MGC-ODT). Some of the elements to be studied include THC, THC metabolite 11-hydroxy-THC, and CBD. An official working with OWC Pharmaceutical Research Corp says that the research involved some healthy adult volunteers.

This research was conducted at the Sourasky Medical Center, which is situated in Tel Aviv. The study will help deliver top-notch products to consumers on a nationwide scale and even beyond borders.

One of the lede researchers reveals that the persons participating in the study were administered randomly. As outlined earlier, the products in question were OWC-ODT (4.2 mg THC, 5 mg CBD) and Sativex (5.4 mg THC, 5.0 mg CBD). The study also involved a two weeks cross over period.

Results of the study

 The researcher also revealed that after 24 hours of the product administration, plasma would be collected from the volunteers. The other thing would be to monitor the effects of the products, and then the researchers would go to the next step. Probably, that would be the checking out as well as the quantification of the THC, CBD, and 11-OH-THC concentrations. The determination of the plasma PK will be important in writing down the final report.

The TLR indicates that both the administration of both MGC-ODT and Sativex® pulled along with rather similar mean times. This was specifically in terms of half-life, peak concentration, and eventually, the elimination rates.

One unique aspect of the results is how they showed some dose-related comparability for the products in terms of bioavailability and absorption. Another important point worth noting is that the treatment incidence showed the related adverse events (AEs), indicating a lot of similarities between the administered treatments.

Continue Reading

Business

Glance Technologies Inc (OTCMKTS:GLNNF) Communicates To Shareholder Through A Letter

Published

on

Glance Technologies Inc (OTCMKTS:GLNNF) owns the dynamic mobile payment and loyalty technology platform known as Glance Pay®. Today, the CEO of the company Jonathan Hoyles has written a letter to the shareholder in the company. This is the first letter the official is writing to them in the position of the company’s Interim CEO.

Hoyles and his words for shareholders

Hoyles wants all shareholders to understand everything regarding the operations and plans. Through this letter, shareholders get to understand what the company intends to over the coming six to twelve months.

The company’s CEO discloses that a short while back, they set some clear measures and goals to help the company move forward. The target is to achieve the set goals within a short time. Some analysts that have had the opportunity to read through these goals see them as overly ambitious.

However, Hoyles exudes confidence saying that they have a dependable team in place. According to the official, this is crucial towards the achievement of the company’s set goals. The leader is quick to admit that indeed, progress is a matter that calls for a company’s dedication to taking the necessary risks. He urges everyone, including the shareholders, in the company, to give their support so that they achieve a home run.

Research and developmental plans

In recent times, the company has directed some funds into quantitative and qualitative market research. Some of the activities it has found helpful include merchant interviews, end-user surveys, and external research. One thing coming out pretty clearly is the fact that most of the end-users seek to be rewarded for their continued loyalty to the company and its diverse products.

Asides from this, they are calling out to the company to move with speed in setting up more restaurant locations for them. It is worth noting that users greatly appreciate the company’s support in helping them pay bills easily and quickly. However, the company thinks it needs to do more than offer them convenience. It wants to move a step further to give them suggestions on items that they need to try out.

Further improvements will be made in marketing and branding, sales and distribution, and also in the enhancement of customer experience. Howles says that they will focus on the right priorities. To him, the best thing is for the company to move its resources to areas of greater yield and productivity.

Continue Reading

Business

Green Organic Dutchman Holdings (OTCMKTS:TGODF) To Review Financing Alternatives For Construction Purposes

Published

on

Green Organic Dutchman Holdings (OTCMKTS:TGODF) has, over the years, been focusing on the production of premium organic cannabis products. The business guru has today disclosed details about its credit financing. According to its spokesperson, the company needs to complete the construction of a number of its business facilities. The facilities are in Ontario, Ancaster, and Phase 1a at Valleyfield, Quebec. Lately, the business has been reviewing some financial alternatives to see the ones to settle for.

The turn of events

In a statement, the company has revealed that the market conditions have been very dynamic and thus need from proper planning. It has, in the past, held discussions regarding some commercial bank facilities and equipment leasing in a bid to identify what would work. The company admits that the discussions were fruitful since it was able to chart the way forward. However, the main point of the discussion wasn’t arrived at. That was because most of the financing sources turned out to be inappropriate. The company says that most of them did not match the required timeframes. It says it had no otherwise but to start reviewing other alternatives.

Plans moving forward

The completion of these facilities is a costly undertaking, but the company seems quite determined.

An official working with The Green Organic Dutchman Holdings but who wanted his identity kept anonymous has made a point. He says that the company, at the moment, has no debt. However, it has about $56.7 million available in cash in Canada. It also has some $40.2 million that will take care of the company’s capital expenditures. The construction activities at the Ancaster are almost reaching completion according to sources. The business giant says that in a matter of about 6-weeks, it will have completed the construction activities here.

Green Organic Dutchman Holdings is optimistic it will get the financing that it requires. In that particular regard, it will channel the funds towards accelerating its commercial production. The goal is to increase its revenues by a significant margin.

So far, the company has gotten into several supply agreements. Some of them are with Alberta, British Columbia, and Ontario. The deal is to engage in the distribution of products on a nationwide scale.

Continue Reading
Advertisement

Trading Symbol

OTC: PLSI

The Next Big Global Cannabis Trade


FEATURED STORIES

Business20 hours ago

OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) Subsidiary’s Cannabis Product Performs Remarkably

Post Views: 171 OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) is an industry leader in the development of cannabinoid-based therapies. Some of...

Business21 hours ago

Glance Technologies Inc (OTCMKTS:GLNNF) Communicates To Shareholder Through A Letter

Post Views: 66 Glance Technologies Inc (OTCMKTS:GLNNF) owns the dynamic mobile payment and loyalty technology platform known as Glance Pay®....

Business2 days ago

Green Organic Dutchman Holdings (OTCMKTS:TGODF) To Review Financing Alternatives For Construction Purposes

Post Views: 138 Green Organic Dutchman Holdings (OTCMKTS:TGODF) has, over the years, been focusing on the production of premium organic...

Business2 days ago

HEXO (OTCMKTS:HYYWF) Expects To Post Net Revenues Of $16.5 Million in Q4 2019 And $48.5 Million For FY 2019

Post Views: 133 HEXO (OTCMKTS:HYYWF) expects to post net revenues of up to $16.5 million in Q4 2019. The company...

Business5 days ago

LeafBuyer Technologies Inc. (OTCMKT:LBUY) Reports 59% YoY Growth In Revenue Following Optimization Of Its Platforms

Post Views: 218 LeafBuyer Technologies Inc. (OTCMKT:LBUY) has announced that its annual revenue for FY 2019 grew by 59%, reflecting...

Business5 days ago

High Tide Inc. (OTCMKTS:HITIF) Report Impressive Q3 Financial Results with Revenue Growing 281%

Post Views: 171 High Tide Inc. (OTCMKTS:HITIF) has announced an inspiring financial result for its third quarter of 2019. The...

Business6 days ago

Kalytera Therapeutics Inc (OTCMKTS:KALTF) Provides Details About Its Latest Notice Of Allowance

Post Views: 156 Kalytera Therapeutics Inc (OTCMKTS:KALTF) has today revealed details regarding the EU Patent Application Number 14791611.8. According to...

Business6 days ago

Pharmacyte Biotech Inc (OTCMKTS:PMCB) Engages Cellular Biologist David A. Judd In An Interview

Post Views: 835 Pharmacyte Biotech Inc (OTCMKTS:PMCB) uses its live-cell encapsulation technology known as Cell-in-a-Box®  for the treatment of diabetes...

Business7 days ago

CV Sciences Inc (OTCMKTS:CVSI) enters a Distribution Agreement With Harris Teeter

Post Views: 150 CV Sciences Inc (OTCMKTS:CVSI) today announced its business collaboration with Harris Teeter. These two business giants target...

Business7 days ago

Tetra Bio Pharma Inc (OTCMKTS:TBPMF) Speaks Out On Its CAUMZ(TM) Kit

Post Views: 160 Tetra Bio Pharma Inc (OTCMKTS:TBPMF) is one of the leaders in the cannabinoid-based therapeutics sector. Some of...

Whats Hot

CULTIVATING

SHAREHOLDER VALUE

 

Trading Symbol

CSE: CHOO
OTCQB: CHOOF

Choom Holdings Inc. CSE: CHOO | OTCQB: CHOOF